Results 1 to 10 of about 1,197 (187)

Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report [PDF]

Nature and Science of Sleep, 2020
Gaia Pellitteri,1,2 Pierluigi Dolso,1 Mariarosaria Valente,1,2 Gian Luigi Gigli1– 3 1Clinical Neurology Unit, Department of Neurosciences, Udine University Hospital, Udine, Italy; 2Department of Medicine (DAME), University of Udine, Udine, Italy ...
Pellitteri G, Dolso P, Valente M, Gigli GL   +3 more
doaj   +7 more sources

Pentylenetetrazol-induced seizures and brain neuroinflammation markers under conditions of pitolisant and pioglitazone use [PDF]

Journal of Education, Health and Sport
The purpose of the study was to investigate the dynamics of seizure activity and markers of neuroinflammation in kindled rats under conditions of individual and combined use of pitolisant and pioglitazone.
O. Yehorenko, M. Pervak
doaj   +4 more sources

Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety

Pharmacology Research & Perspectives
Pitolisant, a novel histamine H3‐receptor antagonist, holds significant promise for treating narcolepsy. However, a petition, which highlighted that pitolisant was associated with deaths during clinical trials, has propelled it into the spotlight of ...
Cheng Jiang, Jiancheng Qian, Xin Jiang, Shuohan Zhang, Junxian Zheng, Hongwei Wang   +5 more
doaj   +2 more sources

Pitolisant alleviates brain network dysfunction and cognitive deficits in a mouse model of Alzheimer’s disease

Translational Psychiatry
Histamine H3 receptor (H3R) antagonists regulate histamine release that modulates neuronal activity and cognitive function. Although H3R is elevated in Alzheimer’s disease (AD) patients, whether H3R antagonists can rescue AD-associated neural impairments
Yang Zou, Linhan Yang, Jiahui Zhu, Jihua Fan, Hanrun Zheng, Xiang Liao, Zhiqi Yang, Kuan Zhang, Hongbo Jia, Arthur Konnerth, Yan-jiang Wang, Chunqing Zhang, Yun Zhang, Sunny C. Li, Xiaowei Chen   +14 more
doaj   +2 more sources

Acute hypobaric hypoxia attenuates the anti-fatigue effects of pitolisant by downregulating the expression of organic cation transporter 1 and P-glycoprotein

Frontiers in Pharmacology
ObjectiveThis study investigates the effects of acute hypobaric hypoxia (HH) on the anti-fatigue properties of pitolisant and explores the underlying mechanisms.
Gang Zhao, Yajuan Li, Mengyuan Liu, Mengyuan Liu, Wei Chang, Hui Shen, Junhui Xue, Junhui Xue, Junhui Xue, Fengzhou Liu, Fengzhou Liu   +10 more
doaj   +2 more sources

Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study. [PDF]

Sleep Medicine
BACKGROUND Narcolepsy is a chronic sleep disorder characterized mainly by excessive daytime sleepiness (EDS) and cataplexy in the case of narcolepsy type 1 (NT1).
G. Plazzi, Geert Mayer, Ralf Bodenschatz, Enrica Bonanni, A. Cicolin, Giacomo Della Marca, Pierluigi Dolso, L. Strambi, Raffaele Ferri, Peter Geisler, Svenja Happe, A. Heidbreder, Jürgen Herold, U. Kallweit, Laurène Leclair-Visonneau, Katharina Lederer, Claudio Liguori, Johan Meurling, L. Parrino, P. Proserpio, M. Puligheddu, M. Quera Salva, J. Rémi, A. Romigi, Sven Rupprecht, M. Savarese, Jean-Luc Schaff, M. Terzaghi, Y. Winter, C. Caussé, Irène Collin, I. Lecomte, Yves Dauvilliers   +32 more
semanticscholar   +3 more sources

Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial. [PDF]

Lancet Neurology, 2023
BACKGROUND Narcolepsy is a life-long disorder characterised by excessive daytime sleepiness and cataplexy, often arising in childhood or adolescence. Pitolisant, a selective histamine H3 receptor inverse agonist, has been approved in Europe and USA for ...
Y. Dauvilliers, M. Lecendreux, G. Lammers, Patricia Franco, M. Poluektov, C. Caussé, I. Lecomte, J. Lecomte, P. Lehert, J. Schwartz, G. Plazzi   +10 more
semanticscholar   +3 more sources

Increased Sensitivity of Mice Lacking Extrasynaptic δ-Containing GABAA Receptors to Histamine Receptor 3 Antagonists [PDF]

Frontiers in Pharmacology, 2020
Histamine/gamma-aminobutyric acid (GABA) neurons of posterior hypothalamus send wide projections to many brain areas and participate in stabilizing the wake state.
Shamsiiat Abdurakhmanova, Milo Grotell, Jenna Kauhanen, Anni-Maija Linden, Esa R. Korpi, Pertti Panula   +5 more
doaj   +3 more sources

Utilizing quality by design methodology for liquid chromatography method development and validation in quantifying impurities in Pitolisant, a Histamine-3 (H3) receptor antagonist/inverse agonist

Results in Chemistry
We developed and validated a liquid chromatography technique to determine organic impurities of Pitolisant in Pitolisant film-coated tablets (4.45 mg and 17.8 mg), a medication used to treat excessive daytime drowsiness.
Jayaprakash Kanijam Raghupathi, Lova Gani Raju Bandaru, Kiran Kumar Madineni, Mastan Ali Syed, Sreekantha Babu Jonnalagadda, D. Ramachandran, Naresh Kumar Katari   +6 more
doaj   +2 more sources

Pitolisant nanofibers: A promising frontier in drug delivery for narcolepsy - Formulation, optimisation, and characterization insights

Biomedical Technology
The study focuses on developing a new way to deliver the narcolepsy medication pitolisant. Electrospinning was used to make polyvinyl alcohol (PVA) and hyperbranched polyglycerol (HPG) polymers into pitolisant nanofibers (PT-NF).
J. Nandhini, E. Karthikeyan, C. Jegatheshwaran, K. Vignesh, G. Muthuboopathi, S. Rajeshkumar   +5 more
doaj   +2 more sources